Discover a treatment for SMA that’s directly delivered to the central nervous system to target an underlying cause of motor neuron loss in SMA.1,2

have been treated with SPINRAZA worldwide3*

there’s someone from almost every age group who has taken SPINRAZA1,3

have been treated with SPINRAZA worldwide3*

*Based on commercial patients, early access patients, and clinical trial participants through December 2019.
Includes clinical trial patients.
Clinical studies of SPINRAZA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients.
§Based on commercial patients in the US (including Puerto Rico) through December 2019.

How does SPINRAZA work?

SPINRAZA is an antisense oligonucleotide
designed to target an underlying cause of
motor neuron loss in SMA.1

Proven efficacy in a broad range of SMA types

SPINRAZA is the treatment that’s been studied in the longest clinical trial program in SMA to date.3

The most common side effects of SPINRAZA include lower respiratory infection, pyrexia, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA.

a later-onset adult patient with spinal muscular atrophy on SPINRAZA
a later-onset adult patient with spinal muscular atrophy on SPINRAZA
a later-onset adolescent patient with spinal muscular atrophy on SPINRAZA
a later-onset adolescent patient with spinal muscular atrophy on SPINRAZA

10,000+ patients have been treated
with SPINRAZA worldwide3*

*Based on commercial patients, early access
patients, and
clinical trial participants through
December 2019.

Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.

a later-onset pediatric patient with spinal muscular atrophy on SPINRAZA
a later-onset pediatric patient with spinal muscular atrophy on SPINRAZA

Get to know our patient support

The Biogen SMA360°™ support program provides services for patients and their families that address nonmedical barriers to access.

a later-onset adult patient with spinal muscular atrophy on SPINRAZA

“When you’re living with
SMA, it really is about
the small victories.”

—Bill